Edgewise Therapeutics, Inc.
EWTX
$13.45
$0.423.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -33.60% | -38.98% | -42.67% | -39.61% | -48.08% |
| Total Depreciation and Amortization | 32.22% | 69.95% | 117.83% | 209.20% | 221.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 51.27% | 42.17% | 4.88% | -15.72% | -22.52% |
| Change in Net Operating Assets | 762.05% | -22.82% | -68.47% | -167.86% | -138.18% |
| Cash from Operations | -18.58% | -41.48% | -54.89% | -55.38% | -74.69% |
| Capital Expenditure | 77.16% | 86.49% | 88.35% | 82.46% | -3.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -268.78% | -2,031.58% | -352.09% | -390.57% | 267.04% |
| Cash from Investing | -279.48% | -58,274.27% | -265.22% | -305.25% | 245.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 367.86% | 76,123.41% | 127.42% | 126.06% | -59.06% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -58.79% | -65.12% | -7,200.00% | 34.26% | 34.26% |
| Cash from Financing | 368.82% | 241,507.26% | 127.93% | 127.04% | -58.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -169.31% | 115.43% | -13.28% | -230.41% | 897.42% |